Evaluation ofp53 alterations in occult lymph node metastases

Molecular assessment of lymph nodes in patients with resected stage I non–small cell lung cancer: Preliminary results of a prospective study

“…These percentages are similar to numbers obtained with immunohistochemical methods. [4][5][6][7]15 Long-term survival was not diminished among the patients with micrometastases, although this may reflect the small sample size (n = 9). In addition, TP53 and K-ras mutations in themselves may negatively affect survival, thereby limiting the ability to detect a further impact of molecular metastases on survival.…”

“…With these techniques, cytokeratin-positive cells have been detected in 4% to 17% of the regional lymph nodes from patients with resected stage I disease, leading to a change in stage for 15% to 70% of patients. [4][5][6][7]15 In several studies cytokeratin-positive cells in regional lymph nodes have been found to be associated with a decrease in diseasespecific survival. 5,7,15 Immunohistochemical methods have also been used to detect occult metastases in the bone marrow of patients with NSCLC.…”

“…[4][5][6][7]15 In several studies cytokeratin-positive cells in regional lymph nodes have been found to be associated with a decrease in diseasespecific survival. 5,7,15 Immunohistochemical methods have also been used to detect occult metastases in the bone marrow of patients with NSCLC. From 22% to 60% of patients with resectable NSCLC have cytokeratin-positive cells in the bone marrow at the time of resection.…”

Systematic review and meta‐analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage I–IIIA non‐small cell lung cancer

“…Nine articles (56%) were scored as good quality and six articles (37.5%) were scored as fair quality. [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37] Only one article (6.25%) had a poor quality score (<14 points), and was therefore excluded from the final meta-analysis. 38…”

Pretreatment identification of micro-metastasis in mediastinal lymph node by endobronchial ultrasound-guided transbronchial needle aspiration for early-stage non-small cell lung cancer—is it time yet?

“…Despite the lack of a standardized and a uniform approach for the detection of LN MM, evidence exists to support its clinical significance. Multiple studies demonstrate MM as a negative prognostic factor (9,23,24,(26)(27)(28)(29)(30)(31)(32)(33)(34)(35), although other authors disagree (36)(37)(38). Adding credence to the assumption that MM impact prognosis is the finding that the more aggressive the primary tumor subtype is, the higher is the risk of MM in the mediastinal nodes (39,40).…”